<li>amitriptyline<p>esomeprazole will increase the level or effect of amitriptyline by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>amobarbital<p>amobarbital will decrease the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>ampicillin<p>esomeprazole will decrease the level or effect of ampicillin by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>armodafinil<p>armodafinil will increase the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>axitinib<p>esomeprazole will increase the level or effect of axitinib by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>bendamustine<p>esomeprazole decreases levels of bendamustine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Consentration of active metabolites may be increased.</p></li><li>bortezomib<p>bortezomib will increase the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>bosentan<p>bosentan will decrease the level or effect of esomeprazole by  increasing metabolism. Use Caution/Monitor.</p></li><li>bosutinib<p>esomeprazole will decrease the level or effect of bosutinib by  increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Bosutinib displays pH dependent solubility</p></li><li>budesonide<p>esomeprazole decreases effects of budesonide by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Enteric-coated budesonide dissolves at pH &gt;5.5. Also, dissolution of extended-release budesonide tablets is pH dependent. Coadministration with drugs that increase gastric pH may cause these budesonide products to prematurely dissolve, and possibly affect release properties and absorption of the drug in the duodenum.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>carbonyl iron<p>esomeprazole will decrease the level or effect of carbonyl iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cefpodoxime<p>esomeprazole will decrease the level or effect of cefpodoxime by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>cefuroxime<p>esomeprazole will decrease the level or effect of cefuroxime by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>citalopram<p>esomeprazole will increase the level or effect of citalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Citalopram 20 mg/day is the maximum recommended dose for patients taking CYP2C19 inhibitors because of the risk of QT prolongation.</p></li><li>clobazam<p>esomeprazole will increase the level or effect of clobazam by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Dosage adjustment may be required; CYP2C19 inhibitors may result in increased exposure to N-desmethylclobazam (active metabolite).</p></li><li>clozapine<p>esomeprazole will decrease the level or effect of clozapine by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>crizotinib<p>esomeprazole decreases levels of crizotinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that elevate the gastric pH may decrease the solubility of crizotinib and subsequently reduce its bioavailability. However, no formal studies have been conducted. .</p></li><li>crofelemer<p>crofelemer increases levels of esomeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>cyclosporine<p>esomeprazole, cyclosporine.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: When used for prolonged periods of time PPIs may cause hypomagnesemia and the risk is further increased when used concomitantly with drugs that also have the same effects.</p></li><li>dabrafenib<p>esomeprazole will decrease the level or effect of dabrafenib by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Drugs that alter upper GI tract pH (eg, PPIs, H2-blockers, antacids) may decrease dabrafenib solubility and reduce its bioavailability<span><br><br></span>dabrafenib will decrease the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Monitor Closely. Use alternative if available</p></li><li>dextroamphetamine<p>esomeprazole, dextroamphetamine. Other (see comment). Use Caution/Monitor. 
Comment: Reduced gastric acidity caused by proton pump inhibitors decreases time to Tmax for amphetamine and dextroamphetamine. AUC was unaffected. .</p></li><li>dichlorphenamide<p>dichlorphenamide and esomeprazole both decrease  serum potassium. Use Caution/Monitor.</p></li><li>digoxin<p>esomeprazole increases toxicity of digoxin by Other (see comment). Use Caution/Monitor. 
Comment: Prolonged use of PPIs may cause hypomagnesemia and increase risk for digoxin toxicity.</p></li><li>duloxetine<p>esomeprazole will decrease the level or effect of duloxetine by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>eltrombopag<p>esomeprazole will decrease the level or effect of eltrombopag by  affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.</p></li><li>escitalopram<p>esomeprazole will increase the level or effect of escitalopram by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>etravirine<p>esomeprazole will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.<span><br><br></span>etravirine will increase the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>ferric gluconate<p>esomeprazole will decrease the level or effect of ferric gluconate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous fumarate<p>esomeprazole will decrease the level or effect of ferrous fumarate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous gluconate<p>esomeprazole will decrease the level or effect of ferrous gluconate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ferrous sulfate<p>esomeprazole will decrease the level or effect of ferrous sulfate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>fosamprenavir<p>esomeprazole will decrease the level or effect of fosamprenavir by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>fosphenytoin<p>esomeprazole will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>gefitinib<p>esomeprazole decreases levels of gefitinib by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Avoid coadministration of gefitinib with PPIs if possible. If treatment with a PPI is required, separate gefitinib and PPI doses by 12 hr.</p></li><li>glipizide<p>esomeprazole will increase the level or effect of glipizide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>glyburide<p>esomeprazole will increase the level or effect of glyburide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>iloperidone<p>iloperidone increases levels of esomeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>imipramine<p>esomeprazole will increase the level or effect of imipramine by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>iron dextran complex<p>esomeprazole will decrease the level or effect of iron dextran complex by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>iron sucrose<p>esomeprazole will decrease the level or effect of iron sucrose by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>ledipasvir/sofosbuvir<p>esomeprazole decreases levels of ledipasvir/sofosbuvir by Other (see comment). Use Caution/Monitor. 
Comment: Ledipasvir solubility decreases as pH increases; drugs that increase gastric pH are expected to decrease levels of ledipasvir; proton-pump inhibitor doses comparable to omeprazole &lt;20 mg can be administered simultaneously with ledipasvir/sofosbuvir under fasted conditions.</p></li><li>lumacaftor/ivacaftor<p>lumacaftor/ivacaftor, esomeprazole. affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C19 substrates. .<span><br><br></span>lumacaftor/ivacaftor will decrease the level or effect of esomeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lumacaftor/ivacaftor is a strong CYP3A4 inhibitor and also has the potential to induce CYP2C19 and both induce and inhibitor P-gp.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>methotrexate<p>esomeprazole increases levels of methotrexate by decreasing renal clearance. Use Caution/Monitor. Increased risk of toxicity with higher doses.</p></li><li>mitotane<p>mitotane decreases levels of esomeprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>mycophenolate<p>esomeprazole will decrease the level or effect of mycophenolate by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Potential interaction applies to mycophenolate mofetil. Enteric coated mycophenolate sodium formulation is less sensitive to this interaction. Clinical significance unclear.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>phenytoin<p>esomeprazole will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>polysaccharide iron<p>esomeprazole will decrease the level or effect of polysaccharide iron by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>posaconazole<p>esomeprazole will decrease the level or effect of posaconazole by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>primidone<p>primidone will decrease the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin will decrease the level or effect of esomeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>rifampin will decrease the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>riociguat<p>esomeprazole will decrease the level or effect of riociguat by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>rose hips<p>esomeprazole will decrease the level or effect of rose hips by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.<span><br><br></span>st john's wort will decrease the level or effect of esomeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>sulpiride<p>esomeprazole will decrease the level or effect of sulpiride by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>tacrolimus<p>esomeprazole will increase the level or effect of tacrolimus by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Concomitant administration may increase tacrolimus whole blood concentrations, particularly in intermediate or poor metabolizers of CYP2C19</p></li><li>tolbutamide<p>esomeprazole will increase the level or effect of tolbutamide by  increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>vismodegib<p>esomeprazole will decrease the level or effect of vismodegib by  Other (see comment). Use Caution/Monitor. Drugs that increase gastric pH alter vismodegib solubility and therefore reduce bioavailability; effect on efficacy unknown</p></li><li>voriconazole<p>voriconazole will increase the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.</p></li>